Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls.
about
Contribution of chaperones to STAT pathway signaling.A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasionSmall molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer.Thermo-targeted drug delivery of geldanamycin to hyperthermic tumor margins with diblock elastin-based biopolymers.Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluationExtracellular Hsp90 serves as a co-factor for NF-κB activation and cellular pathogenesis induced by an oncogenic herpesvirus.Interactions between Hsp90 and oncogenic viruses: implications for viral cancer therapeuticsSystematic identification of the HSP90 candidate regulated proteome.Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer.Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells.Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives.The double-edged sword: conserved functions of extracellular hsp90 in wound healing and cancer.Molecular Basis of Pterygium Development.How Selective are Hsp90 Inhibitors for Cancer Cells over Normal Cells?A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.Mechanisms of Resistance to Hsp90 Inhibitor Drugs: A Complex Mosaic Emerges.Macrocycles that inhibit the binding between heat shock protein 90 and TPR-containing proteins.Chemically accessible hsp90 inhibitor that does not induce a heat shock responseA heat shock protein 90 inhibitor that modulates the immunophilins and regulates hormone receptors without inducing the heat shock responseHSP90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and HSP90 signaling network complex in leukemia cells.Curcumin inhibited HGF-induced EMT and angiogenesis through regulating c-Met dependent PI3K/Akt/mTOR signaling pathways in lung cancer.Effectively delivering a unique hsp90 inhibitor using star polymers.Dimerization of a heat shock protein 90 inhibitor enhances inhibitory activity.Tumour eradication using synchronous thermal ablation and Hsp90 chemotherapy with protein engineered triblock biopolymer-geldanamycin conjugates.Hsp90 and angiogenesis in bone disorders--lessons from the avian growth plate.
P2860
Q27687561-2D095F1F-6823-445D-8084-5A1305626786Q28477362-8224CB23-97E1-4DDF-B257-3E631D3F5E4AQ33688577-E4D999B7-BCF8-4E7D-B35E-4D6D52C85F1EQ33917356-E0FDA77A-F12B-48A8-B282-E01F87838CCBQ33994250-6703FC84-3D2E-42E0-9171-C58D8806FF4DQ34102029-929B2435-9994-4912-BBDE-99C7F11403EDQ35298119-2A1DBDF2-B6ED-472A-84E9-AC082C9D7933Q35376259-B8CEA617-64CB-448F-ADA5-8D503A4FEF39Q36209058-733CC7ED-7D2C-4970-BFB9-E8EB1D3AFA41Q36368188-B3571559-B169-4960-8BA4-B3CD7FAE772BQ36847206-EA410D6A-629D-4C64-BEC6-60DE4895A2E9Q37998372-EABE4384-27CC-4772-8FA7-9ED4BBA813E8Q38210012-B77955B4-E7FE-4634-8A77-303F819B1B1EQ38270264-BDF4C233-0604-4E6B-9D06-C13BDF46AC40Q38718676-56C98139-6CF7-427E-885B-BBC3D282F8CBQ38740513-CEBA45B1-9E07-450A-8E76-DF84ADB17AECQ38976702-FFE20776-2A4F-4A69-8945-6007B4F606C6Q39894584-747C3AC1-029B-447B-AED3-43089B13197AQ41863286-E8D5223D-B93E-4A85-AD36-821559D939C9Q41864092-37A62499-C99C-4DE4-A8CF-2E00E037668EQ42110946-57FF9527-1526-41F8-9741-BEC59CFDB6E4Q42382997-7F4C9F18-DC56-4FCF-AF58-77430AFCC0DDQ42774352-47688370-36C8-4105-956F-B50063CE924CQ45731359-086CF8AE-9DA9-460D-845E-A5E710D73CD7Q53390739-F00ADE85-BD77-4399-8968-CE1042366EAEQ54590776-B9767B00-0633-45F5-BEE1-4B9AF0943C57
P2860
Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls.
@en
Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls.
@nl
type
label
Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls.
@en
Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls.
@nl
prefLabel
Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls.
@en
Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls.
@nl
P2860
P356
P1433
P1476
Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls
@en
P2093
J E Bohonowych
J S Isaacs
P2860
P304
P356
10.1155/2010/412985
P577
2010-06-24T00:00:00Z